PolyPeptide Group (Hangzhou): difference between revisions
Diff·revision 23 → 24·11:44, 21 Feb 2026
Difference between revision 23 and revision 24 of PolyPeptide Group (Hangzhou). 4 lines changed; the page grew by 860 bytes.
| Revision 23 — 02:56, 9 Feb 2026 CheckSumChase (talk) convert a hard-coded date to the house format 16,562 bytes ±0 | Revision 24 — 11:44, 21 Feb 2026 StopperingSteff (talk) add the reception tally with its period and count stated 17,422 bytes +860 | ||
|---|---|---|---|
| 104 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | 104 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} |
| 105 | 105 | ||
| + | 106 | Two frameworks are named in this article only to say what has ''not'' been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,{{r|gmp}} and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.{{r|iso17025}} Neither assessment is available here for this organisation or for any other covered on this wiki. | |
| + | 107 | ||
| 106 | == References == | 108 | == References == |
| 107 | {{reflist}} | 109 | {{reflist}} |
| ⋮ | ⋮ | ||
| 111 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 113 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 112 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 114 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 115 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 113 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 116 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 117 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| 114 | 118 | ||
| 115 | == Further reading == | 119 | == Further reading == |